To further confirm KLF2 expression differences between intestinal-type and diffuse-type gastric cancers, we analyzed epigenomic promoter activity [as measured by H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq)] and gene expression of KLF2 in an independent bulk RNA data set of 24 gastric cancers (9 diffuse-type and 14 intestinal-type). This evidence concerns the gene KLF2 and gastric cancer.